Our camelid monoclonal vHH nanobody platform enables rapid antibody discovery and development from target identification through lead optimization. Single cell sorting of antigen specific llama and alpaca B cells delivers high quality vHH sequences in as little as three weeks. This sequence driven approach reduces development time and cost while preserving native antibody diversity for improved affinity and epitope coverage. Integrated in silico developability assessment, including humanization and immunogenicity prediction, supports efficient selection of development ready therapeutic candidates.